Recent Quotes (30 days)

You have no recent quotes
chg | %

Oxford BioMedica plc  

(Public, LON:OXB)   Watch this stock  
Find more results forOXB
0.00 (0.00%)
Sep 25 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 8.70 - 9.16
52 week 2.98 - 11.25
Open 8.70
Vol / Avg. 2.42M/2.95M
Mkt cap 271.80M*
P/E     -
Div/yield     -
EPS 0.00*
Shares 3,103.79M
Beta     -
Inst. own     -
Sep 27, 2017
Oxford BioMedica PLC at Cantor Fitzgerald Global Healthcare Conference - 9:35pm BST - Add to calendar
Sep 12, 2017
Oxford BioMedica PLC at Rodman & Renshaw Global Investment Conference
Aug 17, 2017
Half Year 2017 Oxford BioMedica PLC Earnings Call
Aug 17, 2017
Half Year 2017 Oxford BioMedica PLC Earnings Release

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -21.31% -59.91%
Operating margin -14.15% -40.73%
EBITD margin - -27.22%
Return on average assets -11.53% -30.59%
Return on average equity -56.98% -141.57%
Employees 247 -
CDP Score - -


Windrush Court, Transport Way
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

Officers and directors

John Dawson Chief Executive Officer, Executive Director
Age: 56
Stuart Paynter Chief Financial Officer, Director
Peter Nolan Executive Director, Chief Business Officer
Age: 62
Lorenzo Tallarigo M.D. Non-Executive Chairman of the Board
Age: 64
Andrew J. Heath M.D., Ph.D. Non-Executive Deputy Chairman of the Board, Senior Independent Director
Age: 66
Martin Diggle Non-Executive Director
Age: 52
Stuart Henderson Non-Executive Director